5-氨基戊基氨基甲酸苄酯 | 69747-36-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-氨基戊基氨基甲酸苄酯
• 英文名称: (5-aminopentyl)carbamic acid benzyl ester
• 英文别名: benzyl (5-aminopentyl)carbamate；N-benzyloxycarbonyl-1,5-diamino-pentane；Benzyl N-(5-aminopentyl)carbamate
• CAS: 69747-36-0
• 化学式: C₁₃H₂₀N₂O₂
• mdl: MFCD01318870
• 分子量: 236.314
• InChiKey: ZZRXQSABHQZWCC-UHFFFAOYSA-N

物化性质

• 熔点：
  172-175 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  17
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38

反应信息

• 作为反应物：
  描述：

  5-氨基戊基氨基甲酸苄酯 在 sodium hydroxide 、 碳酸氢钠 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 97.0h， 生成
  参考文献：
  名称：

  Probing the functional requirements of the l-haba side-chain of amikacin—synthesis, 16S A-site rRNA binding, and antibacterial activity

  摘要：

  The 1-amino group in amikacin was acylated with a variety of 2-hydroxy aminocarboxylic acids to probe the effect of acylation on ribosomal binding and antibacterial activity. The N-hydroxy urea analogue of amikacin (8a) in which the 2-S-hydroxyl-bearing carbon was replaced by an N-OH group was equally active against S. aureus and E. coli in vitro. The analogous tobramycin variant 9 was more active than amikacin. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(02)01625-3
• 作为产物：
  描述：

  5-氨基-1-戊醇 在 palladium on activated charcoal 、 乙二胺 sodium azide 、 氢气 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 60.0h， 生成 5-氨基戊基氨基甲酸苄酯
  参考文献：
  名称：

  Pd/C(en)-Catalyzed Chemoselective Hydrogenation with Retention of the N-Cbz Protective Group and its Scope and Limitations

  摘要：

  A chemoselective method for the hydrogenation of acetylene, olefin, azide, nitro and benzyl ester functionalities with retention of the aliphatic N-Cbz group was established. The chemoselectivity was accomplished by using a combination of 5% Pd/C-ethylenediamine [5% Pd/C(en)] and THF (or 1,4-dioxane) as a solvent, and the scope and limitations of this methodology were investigated. These results reinforce the utility of N-Cbz protective groups in synthetic chemistry, especially in peptide synthesis (C) 2000 Elsevier Science Ltd. All lights reserved.

  DOI：

  10.1016/s0040-4020(00)00771-7

文献信息

• [EN] COMPOUNDS FOR THE TREATMENT OF HEPATITIS C<br/>[FR] COMPOSÉS DESTINÉS AU TRAITEMENT DE L'HÉPATITE C
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2012141704A1

  公开（公告）日：2012-10-18

  The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

  该披露提供了公式I的化合物，包括药用可接受的盐，以及使用这些化合物的组合物和方法。这些化合物对丙型肝炎病毒（HCV）具有活性，并可能对感染HCV的人有用。
• Inositol-phosphate derivatives and method of detecting inositol-1-phosphate
  申请人：CIS Bio International

  公开号：US08178704B2

  公开（公告）日：2012-05-15

  The present invention relates to inositol phosphate derivatives, in which the inositol phosphate is substituted with one or two reactive groups G or one or two conjugated substances or molecules M, said reactive group(s) G or said substance(s) or molecule(s) M being linked to IP1 via a linkage group L, M being chosen from the following group: a tracer, an immunogen, a member of a binding partner pair, a solid support. Application: tools allowing the study of the inositol phosphate cycle and therefore, indirectly, the study of seven transmembrane domain receptors coupled to phospholipase C, receptors having a tyrosine kinase activity, and in general enzymes involved in the variations of the intracellular concentration of IP1.

  本发明涉及肌醇磷酸衍生物，其中肌醇磷酸被一个或两个反应基团G或一个或两个共轭物质或分子M取代，所述反应基团G或所述物质或分子M通过连接基团L与IP1相连，M选择自以下组：示踪剂、免疫原、结合伙伴对的成员、固体支持。应用：工具，允许研究肌醇磷酸循环，因此间接地研究与磷脂酶C偶联的七膜跨膜结构受体、具有酪氨酸激酶活性的受体，以及一般参与细胞内IP1浓度变化的酶。
• Macrocyclic pyrimidines, their production and use as pharmaceutical agents
  申请人：Schering AG

  公开号：US20040209895A1

  公开（公告）日：2004-10-21

  Macrocyclic pyrimidine derivatives of general formula I 1 in which R 1 to R 5 , X, Y, A, B, m and n have the meanings that are contained in the description, as inhibitors of the cyclin-dependent kinase, their processes for production as well as their use as medications for treating various diseases are described.

  通用公式I的大环嘧啶衍生物 其中R1至R5，X，Y，A，B，m和n的含义如描述中所含，作为细胞周期依赖性激酶抑制剂，它们的生产过程以及它们作为治疗各种疾病的药物的用途被描述。
• Discovery, synthesis, and structure–activity studies of tetrazole based growth hormone secretagogues
  作者：Andrés S. Hernández、Peter T.W. Cheng、Christa M. Musial、Stephen G. Swartz、Rocco J. George、Gary Grover、Dorothy Slusarchyk、R. Krishna Seethala、Mark Smith、Kenneth Dickinson、Leah Giupponi、Daniel A. Longhi、Neil Flynn、Brian J. Murphy、David A. Gordon、Scott A. Biller、Jeffrey A. Robl、Joseph A. Tino

  DOI：10.1016/j.bmcl.2007.07.099

  日期：2007.11

  Growth Hormone Secretagogues (GHS), based on a tetrazole template, has been discovered. In vitro SAR and in vivo potency within this new class of GHS are described. The tetrazole 9q exhibits good oral bioavailability in rats and dogs as well as efficacy following an oral 10 mg/kg dose in dogs. Solution and solid phase protocols for the synthesis of tetrazole based GHS have been developed.

  基于四唑模板，发现了一类新型的生长激素促分泌素（GHS）。描述了这种新型GHS中的体外SAR和体内效价。四唑9q在大鼠和狗中表现出良好的口服生物利用度，以及在狗中口服10 mg / kg剂量后的功效。已经开发了用于合成基于四唑的GHS的溶液和固相方案。
• Structure-Based Design and Development of Chemical Probes Targeting Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 Infectivity
  作者：Boshi Huang、Huiqun Wang、Yi Zheng、Mengchu Li、Guifeng Kang、Victor Barreto-de-Souza、Nima Nassehi、Pamela E. Knapp、Dana E. Selley、Kurt F. Hauser、Yan Zhang

  DOI：10.1021/acs.jmedchem.1c00408

  日期：2021.6.10

  Crystal structures of ligand-bound G-protein-coupled receptors provide tangible templates for rationally designing molecular probes. Herein, we report the structure-based design, chemical synthesis, and biological investigations of bivalent ligands targeting putative mu opioid receptor C–C motif chemokine ligand 5 (MOR-CCR5) heterodimers. The bivalent ligand VZMC013 possessed nanomolar level binding

  配体结合的 G 蛋白偶联受体的晶体结构为合理设计分子探针提供了有形的模板。在此，我们报告了针对假定的 mu 阿片受体 C-C 基序趋化因子配体 5 (MOR-CCR5) 异二聚体的二价配体的基于结构的设计、化学合成和生物学研究。二价配体VZMC013对 MOR 和 CCR5 均具有纳摩尔水平的结合亲和力，抑制 CCL5 刺激的钙动员，并比先前报道的二价配体显着提高抗 HIV-1 BaL活性。VZMC013比单独表达CCR5的细胞更大程度地抑制共表达CCR5和MOR的TZM-bl细胞中的病毒感染。此外，VZMC013以浓度依赖性方式阻断人类免疫缺陷病毒 (HIV)-1 进入外周血单核细胞 (PBMC) 细胞，并且在植物血凝素刺激的 PBMC 细胞中比不存在时更有效地抑制阿片类药物加速的 HIV-1 进入。阿片类药物。构建了VZMC013与 MOR-CCR5 异二聚体复合物结合的三维分子模型，